Reference
FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions Internet Document : 1 Sep 2021. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death?utm_medium=email&utm_source=govdelivery
Rights and permissions
About this article
Cite this article
FDA requires updated safety warnings for Janus kinase inhibitors. Reactions Weekly 1872, 2 (2021). https://doi.org/10.1007/s40278-021-01928-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-01928-z